The quarter's results paint a picture of a company navigating challenging IT spending conditions whilst attempting to maintain growth momentum. Whilst revenue reached an all-time high of ₹985.25 crores, marking the seventh consecutive quarter of revenue growth, profitability metrics reveal concerning trends. Operating margins contracted to 15.36% from 16.07% in the previous quarter, reflecting rising employee costs that grew faster than revenue. The stock, currently trading at ₹1,690.00, has shed 40.02% from its 52-week high of ₹2,817.75, with investors expressing concerns over slowing growth momentum and sustained margin pressure in a competitive IT services landscape.
Financial Performance: Revenue Growth Masks Margin Erosion
Mastek's Q1 FY27 revenue performance demonstrated resilience with net sales of ₹985.25 crores, up 5.04% sequentially and 7.71% year-on-year. This marks the company's highest-ever quarterly revenue, continuing a steady growth trajectory that has seen sales expand from ₹869.53 crores in December 2024 to the current level. However, the revenue growth story is tempered by deteriorating profitability metrics that warrant investor attention.
| Metric | Jun'26 | Mar'26 | Dec'25 | Sep'25 | Jun'25 |
|---|---|---|---|---|---|
| Net Sales (₹ Cr) | 985.25 | 938.00 | 905.68 | 940.37 | 914.70 |
| QoQ Growth | +5.04% | +3.57% | -3.69% | +2.81% | +1.02% |
| Net Profit (₹ Cr) | 105.88 | 106.15 | 108.35 | 97.45 | 92.05 |
| QoQ Growth | -0.25% | -2.03% | +11.19% | +5.87% | +13.54% |
| Operating Margin % | 15.36% | 16.07% | 16.78% | 15.47% | 15.01% |
| PAT Margin % | 10.75% | 11.32% | 11.96% | 10.36% | 10.06% |
The margin compression story is particularly concerning. Operating margins (excluding other income) declined 71 basis points quarter-on-quarter to 15.36%, down from a recent peak of 16.78% in December 2025. PAT margins similarly contracted by 57 basis points to 10.75%. This erosion stems primarily from employee costs, which surged to ₹532.56 crores in Q1 FY27 from ₹502.98 crores in Q4 FY26, representing a 5.88% sequential increase that outpaced the 5.04% revenue growth. Employee costs now consume 54.04% of revenues, up from 53.62% in the previous quarter, indicating deteriorating operating leverage.
On a positive note, the company's tax efficiency improved with the effective tax rate declining to 23.53% in Q1 FY27 from an unusually low 15.24% in Q4 FY26, which had benefited from one-time adjustments. Other income moderated to ₹12.03 crores from ₹23.87 crores in the previous quarter, suggesting the prior period included non-recurring treasury gains. The normalisation of both tax rates and other income provides a cleaner base for assessing core operational performance going forward.
Operational Challenges: Employee Cost Inflation and Margin Pressure
Mastek's operational metrics reveal a company grappling with sector-wide challenges of wage inflation and competitive talent retention pressures. The 5.88% sequential jump in employee costs to ₹532.56 crores represents the steepest quarterly increase in recent periods, outstripping revenue growth and directly impacting profitability. This suggests either fresh hiring to support growth, salary increments effective from the June quarter, or increased subcontracting costs—all of which compress margins in the near term.
⚠️ Margin Pressure Alert
Employee costs surged 5.88% QoQ to ₹532.56 crores, outpacing revenue growth of 5.04%. This resulted in employee costs rising to 54.04% of revenues from 53.62% in Q4 FY26. Operating margins (excluding other income) contracted 71 basis points to 15.36%, marking the lowest level since June 2025. The company faces challenges in improving operating leverage as wage inflation and talent costs remain elevated across the IT services sector.
From a capital efficiency perspective, Mastek demonstrates solid fundamentals despite near-term margin headwinds. The company's return on equity (ROE) stands at a respectable 17.53% on an average basis, though the latest ROE has moderated to 14.34%. Higher ROE indicates efficient capital utilisation and strong profitability relative to shareholder equity, positioning Mastek favourably compared to several mid-tier IT services peers. The company's return on capital employed (ROCE) averaged an exceptional 62.48% over the long term, though recent half-yearly ROCE of 17.01% reflects the impact of acquisitions and increased capital deployment.
Balance sheet quality remains a key strength. Mastek operates as a net cash company with an average net debt-to-equity ratio of -0.17, indicating cash and investments exceed total debt. As of March 2025, the company held cash and cash equivalents of ₹460.00 crores against long-term debt of ₹379.23 crores, providing financial flexibility for growth investments or acquisitions. The debt-to-EBITDA ratio of 0.87 is comfortably low, and interest coverage of 21.40 times demonstrates strong debt servicing capability. Current assets of ₹1,825.85 crores significantly exceed current liabilities of ₹938.45 crores, ensuring robust liquidity.
Industry Context: Navigating Cautious IT Spending Environment
The broader IT services sector continues to face headwinds from cautious enterprise spending, particularly in key markets like the United States and Europe. Whilst digital transformation and cloud migration remain secular growth themes, clients are scrutinising project budgets and extending decision-making cycles. Mid-tier IT services firms like Mastek face intensified competition from both larger global players with scale advantages and nimble boutique firms offering specialised capabilities.
Mastek's focus on specific verticals—healthcare and life sciences, retail, manufacturing, financial services, and government/public sector—provides some insulation through domain expertise. However, the company's relatively modest scale (₹5,239 crores market cap) limits its ability to compete for large transformation deals that increasingly favour Tier-1 players. The company's 7.71% year-on-year revenue growth in Q1 FY27, whilst positive, lags the broader sector recovery witnessed by larger peers who have reported double-digit growth in recent quarters.
Competitive Positioning Concerns
Mastek's revenue growth of 7.71% YoY in Q1 FY27 demonstrates resilience but trails the performance of larger IT services peers who have capitalised on improved demand momentum. The company's operating margins of 15.36% also lag industry leaders who operate at 18-22% margins, reflecting scale disadvantages and higher employee cost ratios. Mastek must demonstrate sustained margin improvement and accelerated growth to narrow this competitive gap.
Peer Comparison: Valuation Discount Reflects Growth Concerns
Mastek's valuation metrics reveal a significant discount to IT services peers, reflecting market scepticism about the company's growth trajectory and margin sustainability. At a price-to-earnings ratio of 12.57x (trailing twelve months), Mastek trades at less than half the peer group average of approximately 53x, though direct comparison is complicated by the wide valuation dispersion within the sector.
| Company | P/E (TTM) | P/BV | ROE % | Div Yield % |
|---|---|---|---|---|
| Mastek | 12.57 | 1.80 | 17.53 | 1.38 |
| AXISCADES Tech. | 86.82 | 9.26 | 10.78 | — |
| Latent View | 31.98 | 3.61 | 11.60 | — |
| ASM Technologies | 97.75 | 19.71 | 14.14 | 0.17 |
| Seshaasai Tech. | 25.22 | 4.24 | — | — |
| Happiest Minds | 25.23 | 3.38 | 19.54 | 1.70 |
Mastek's superior ROE of 17.53% compared to most peers (excluding Happiest Minds at 19.54%) justifies a premium valuation, yet the market assigns a substantial discount. The company's price-to-book ratio of 1.80x is the lowest in the peer set, suggesting the market questions either the sustainability of current profitability or the company's growth prospects. This valuation gap presents potential opportunity for contrarian investors if Mastek can demonstrate margin stabilisation and accelerated growth, or represents justified scepticism if operational challenges persist.
The dividend yield of 1.38% provides modest income support, though the payout ratio of 18.93% suggests the company retains the majority of earnings for reinvestment. Compared to Happiest Minds' 1.70% yield, Mastek offers slightly lower income returns, though both provide limited yield appeal relative to broader market alternatives.
Valuation Analysis: Attractive Entry Point or Value Trap?
Mastek's current valuation presents a complex picture. At ₹1,690.00 per share, the stock trades 40.02% below its 52-week high of ₹2,817.75, reached in mid-2025 before the sustained correction. The P/E ratio of 12.57x appears attractive compared to the industry average of 21x, suggesting potential upside if the company can demonstrate improved execution and margin recovery.
The PEG ratio of 0.76x (P/E divided by earnings growth rate) suggests the stock is undervalued relative to growth prospects, as values below 1.0 typically indicate attractive valuations. However, this metric relies on historical 5-year EBIT growth of 9.93%, which may not reflect current growth momentum. The enterprise value-to-EBITDA multiple of 8.36x and EV-to-sales of 1.32x both sit below sector averages, reinforcing the valuation discount theme.
Book value per share stands at ₹795.84, implying the stock trades at 2.12x book value. Given the ROE of 14.34% (latest), this multiple appears reasonable—companies with ROE above 15% typically command P/BV multiples of 2-3x. The valuation grade of "Attractive" assigned by proprietary models reflects the combination of below-average multiples and solid fundamental metrics, though recent downgrades from "Very Attractive" in early 2025 suggest deteriorating sentiment.
Shareholding Pattern: Institutional Confidence Remains Mixed
Mastek's shareholding pattern reveals evolving institutional sentiment, with notable shifts in recent quarters that merit investor attention. Promoter holding has remained stable at 35.76% in Q1 FY27, with no pledging of shares—a positive indicator of promoter confidence and financial stability.
| Shareholder Category | Jun'26 | Mar'26 | Dec'25 | Sep'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter | 35.76% | 35.76% | 35.77% | 35.79% | 0.00% |
| FII | 7.45% | 8.03% | 10.26% | 11.24% | -0.58% |
| Mutual Funds | 15.50% | 14.94% | 7.74% | 6.30% | +0.56% |
| Insurance | 0.72% | 0.55% | 0.55% | 0.73% | +0.17% |
| Other DII | 3.64% | 3.53% | 4.36% | 4.50% | +0.11% |
| Non-Institutional | 36.93% | 37.18% | 41.31% | 41.44% | -0.25% |
The most striking trend is the sustained exodus of foreign institutional investors (FIIs), whose stake has declined from 11.24% in September 2025 to just 7.45% in June 2026—a cumulative reduction of 3.79 percentage points. This selling pressure from FIIs, who reduced holdings by 58 basis points in Q1 FY27 alone, reflects concerns about growth visibility and margin trajectory. FII participation across 109 funds suggests broad-based rather than concentrated selling.
Conversely, domestic mutual funds have emerged as significant buyers, dramatically increasing their stake from 6.30% in September 2025 to 15.50% in June 2026. The 7.20 percentage point surge in Q4 FY26 represents substantial accumulation, with 12 mutual fund schemes now holding positions. This divergence between foreign and domestic institutional investors suggests differing views on the company's medium-term prospects, with domestic funds potentially seeing value at current depressed levels.
Insurance company holdings remain minimal at 0.72%, up slightly from 0.55% in the previous quarter. Non-institutional holdings have declined from 42.48% a year ago to 36.93%, indicating retail investor capitulation amid the stock's prolonged correction. Overall institutional holdings of 27.31% provide reasonable liquidity and professional oversight, though the FII exodus remains a concern requiring monitoring.
Stock Performance: Sustained Underperformance Across All Timeframes
Mastek's stock performance presents a deeply concerning picture, with sustained underperformance across virtually all timeframes. Currently trading at ₹1,690.00, the stock has declined 3.23% in the latest trading session, underperforming the Sensex's 0.77% decline by 246 basis points. This single-day weakness exemplifies the broader pattern of consistent underperformance.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +0.09% | -0.41% | +0.50% |
| 1 Month | +5.36% | -0.29% | +5.65% |
| 3 Months | -4.21% | -2.10% | -2.11% |
| 6 Months | -19.97% | -6.61% | -13.36% |
| Year-to-Date | -17.60% | -9.80% | -7.80% |
| 1 Year | -36.20% | -6.47% | -29.73% |
| 2 Years | -36.08% | -4.51% | -31.57% |
| 3 Years | -21.50% | +15.27% | -36.77% |
The one-year performance is particularly damaging, with the stock plunging 36.20% compared to the Sensex's 6.47% decline, resulting in negative alpha of 29.73 percentage points. This underperformance extends across multiple timeframes: six-month returns of -19.97% (vs Sensex -6.61%), three-month returns of -4.21% (vs Sensex -2.10%), and year-to-date losses of 17.60% (vs Sensex -9.80%). The consistency of underperformance suggests structural challenges rather than temporary market dislocation.
Mastek has also significantly lagged its sector peers, with the Computers - Software & Consulting sector declining 24.44% over the past year compared to Mastek's 36.20% fall—an underperformance of 11.76 percentage points even relative to a weak sector. The stock's beta of 1.25 indicates higher volatility than the broader market, amplifying both gains and losses. With current volatility at 36.19% and a negative Sharpe ratio, the stock falls into the "high risk, low return" category—an unfavourable risk-reward profile.
The only bright spots emerge in very short-term performance (one week: +0.09%, one month: +5.36%) and ultra-long-term returns (10 years: +1,174.51%), though the latter reflects the stock's much lower base a decade ago. The stock currently trades below all major moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating technical weakness across all timeframes.
Investment Thesis: Quality Business Facing Growth Headwinds
Mastek's investment thesis presents a nuanced picture of a fundamentally sound business navigating near-term operational challenges. The company's quality credentials remain intact—zero promoter pledging, net cash balance sheet, healthy ROE of 17.53%, exceptional long-term ROCE of 62.48%, and institutional holdings of 27.31%. The 5-year sales growth of 16.52% demonstrates a solid growth track record, whilst the debt-to-EBITDA ratio of 0.87 and interest coverage of 21.40x underscore financial stability.
However, several factors constrain the investment case. The 5-year EBIT growth of just 9.93% lags revenue growth, indicating margin pressure is not a new phenomenon. The sustained underperformance against both the Sensex and sector peers over 1-3 year periods suggests the market has legitimate concerns about the company's competitive positioning and growth trajectory. The current mildly bearish technical trend, with the stock trading below all moving averages, indicates momentum remains negative.
The proprietary Mojo Score of 55/100 places Mastek in "HOLD" territory, reflecting this mixed outlook. The score balances attractive valuation (P/E of 12.57x vs industry 21x) and good quality fundamentals against poor long-term growth metrics and consistent market underperformance. The recent upgrade from "Sell" (score 44) to "Hold" (score 55) in October 2025 suggests some improvement, though the stock remains far from "Buy" territory (score 70+).
Key Strengths & Risk Factors
✓ Key Strengths
- Strong Capital Efficiency: ROE of 17.53% and exceptional long-term ROCE of 62.48% demonstrate efficient capital utilisation
- Net Cash Position: Net debt-to-equity of -0.17 provides financial flexibility for growth investments or acquisitions
- Attractive Valuation: P/E of 12.57x vs industry 21x and P/BV of 1.80x suggest significant discount to peers
- Zero Promoter Pledging: Stable 35.76% promoter holding with no pledged shares indicates strong promoter confidence
- Institutional Support: Rising mutual fund holdings (15.50% from 6.30% in Sep'25) suggests domestic institutional confidence
- Consistent Revenue Growth: Seven consecutive quarters of revenue growth with Q1 FY27 reaching all-time high of ₹985.25 crores
- Positive Financial Trend: Short-term financial trend rated "Positive" with highest-ever quarterly revenue
⚠ Key Concerns
- Margin Erosion: Operating margins declined to 15.36% from 16.78% peak, with employee costs rising faster than revenue
- Weak Growth Momentum: 5-year EBIT growth of 9.93% lags revenue growth, indicating structural margin pressure
- Sustained Underperformance: Stock down 36.20% over one year vs Sensex -6.47%, with negative alpha across all medium-term periods
- FII Exodus: Foreign institutional holdings declined from 11.24% to 7.45% over nine months, reflecting waning foreign confidence
- Technical Weakness: Mildly bearish trend with stock trading below all moving averages (5-day through 200-day)
- High Volatility: Beta of 1.25 and volatility of 36.19% indicate higher risk with negative Sharpe ratio
- Sector Underperformance: Lagging sector by 11.76% over one year despite sector-wide weakness
Outlook: What to Watch in Coming Quarters
📈 Positive Catalysts
- Margin Stabilisation: Evidence of employee cost ratio stabilising below 54% of revenues
- Accelerated Revenue Growth: Quarterly growth exceeding 8-10% driven by new deal wins
- Operating Leverage: Demonstration of improving profitability as revenue scales
- Large Deal Announcements: Wins in target verticals (healthcare, retail, government) that signal competitive strength
- Technical Reversal: Stock reclaiming 200-day moving average at ₹1,864.60
🚨 Red Flags
- Further Margin Compression: Operating margins falling below 15% would signal deepening profitability challenges
- Revenue Growth Slowdown: Sequential decline or flattish growth indicating demand weakness
- Continued FII Selling: Foreign holdings declining below 6-7% would indicate sustained institutional pessimism
- Guidance Disappointment: Any negative commentary on deal pipeline or client spending patterns
- Technical Breakdown: Stock falling below ₹1,334.00 (52-week low) would trigger further selling pressure
The coming quarters will prove crucial in determining whether Mastek can stabilise margins, accelerate growth, and regain investor confidence. The company's strong balance sheet and quality credentials provide a foundation for recovery, but execution must improve significantly. Investors should monitor quarterly results closely for evidence of margin stabilisation and improved operating leverage. The current "Hold" rating reflects this wait-and-see approach—existing shareholders can maintain positions given the valuation support, but fresh investors should await clearer evidence of operational improvement before committing capital.
The Verdict: Hold with Caution—Quality Business Facing Execution Challenges
Score: 55/100
For Fresh Investors: Not recommended for fresh purchases at current levels. Whilst valuation appears attractive at 12.57x P/E (vs industry 21x), persistent margin erosion, weak growth momentum (5-year EBIT CAGR of 9.93%), and sustained underperformance across all medium-term timeframes suggest operational challenges that require resolution. The 36.20% decline over the past year and mildly bearish technical trend indicate momentum remains negative. Wait for evidence of margin stabilisation and improved sequential growth before initiating positions.
For Existing Holders: Continue to hold given attractive valuation support and strong balance sheet fundamentals (net cash position, ROE of 17.53%, zero promoter pledging). The stock's 40.02% decline from 52-week highs has created valuation cushion, with P/BV of 1.80x appearing reasonable for a company with 14.34% ROE. However, set a stop-loss at ₹1,334.00 (52-week low) to protect against further downside if operational metrics deteriorate. Monitor quarterly results closely for signs of margin recovery and accelerating growth.
Fair Value Estimate: ₹1,900-2,000 (12-18% upside), contingent on margin stabilisation at 16%+ and sustained revenue growth of 8-10% quarterly. Current price of ₹1,690.00 offers limited margin of safety given execution uncertainties.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The views expressed are based on data available as of July 22, 2026, and are subject to change.
